June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Effects OF CRISPR knockout of the Humanin trimeric CNTFR/gp130/WSX-1 receptor in AMD
Author Affiliations & Notes
  • Sonali R Nashine
    Ophthalmology, University of California Irvine, Irvine, California, United States
  • M.Cristina Kenney
    Ophthalmology, University of California Irvine, Irvine, California, United States
  • Footnotes
    Commercial Relationships   Sonali Nashine None; M.Cristina Kenney None
  • Footnotes
    Support  This work was supported by the Discovery Eye Foundation, Polly and Michael Smith, Iris and the B. Gerald Cantor Foundation, Beckman Initiative for Macular Research, National Institute on Aging [AG006168 to SMJ] and National Eye Institute R01 EY027363 (MCK). We acknowledge the support of the Institute for Clinical and Translational Science (ICTS) at University of California, Irvine. Supported in part by an Unrestricted Departmental Grant from Research to Prevent Blindness. We acknowledge the support of the Institute for Clinical and Translational Science (ICTS) at University of California, Irvine.
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 1861. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sonali R Nashine, M.Cristina Kenney; Effects OF CRISPR knockout of the Humanin trimeric CNTFR/gp130/WSX-1 receptor in AMD. Invest. Ophthalmol. Vis. Sci. 2022;63(7):1861.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : In the AMD (Age-related Macular Degeneration) RPE transmitochondrial cell lines, the protective effects of Humanin G (HNG) mitochondrial derived peptide are mediated through the extracellular trimeric CNTFR/gp130/WSX-1 receptor. Binding of Humanin to this receptor leads to the activation of downstream signaling factors, phosphorylation of JAK2 and STAT3, and transcription of genes that confer cytoprotection in AMD.

Methods : We created a novel CRISPR-edited triple knock-out (KO) cell pool of the extracellular trimeric CNTFR/gp130/WSX-1 receptor genes in a wet AMD RPE transmitochondrial cybrid cell line by sequential knock-out of these genes and performed Sanger sequencing to confirm the knockout. HNG was exogenously added to AMD RPE transmitochondrial cybrid cells, which had identical nuclei from the mitochondria-deficient ARPE-19 cells but differed in mitochondrial DNA (mtDNA) content which was derived from a clinically characterized AMD patient. Cell viability and apoptotic cell death were compared between AMD wild-type (WT) vs. AMD KO cells using the MTT assay and Caspase- 3/7/ NucLight IncuCyte® live-cell imaging.

Results : Sanger sequencing of the KO cell pool results: (1) CNTFR gene: KO score=88 %; Indel=94 %; (2) gp130 gene: KO score=62 %; Indel=64 %; (3) WSX-1 gene: KO score=94 %; Indel=99 %. These results demonstrate successful CRISPR editing of the trimeric receptor genes. There was decreased (P = 0.02) cellular metabolic activity that reflects cell viability in AMD KO untreated cells (0.88 ± 0.03) compared to AMD WT untreated cells (1 ± 0.04). Higher viable cell number (IncuCyte live-cell imaging) was observed in HNG-treated AMD WT cells (1.14 ± 0.02) compared with untreated AMD WT cells (1 ± 0.04, P = 0.03). We found significant reduction (P<0.01) in cell number in untreated AMD KO vs. untreated AMD WT cells. HNG-induced rescue was reduced significantly in AMD KO cells compared to that in AMD WT cells (P<0.05).

Conclusions : The CRISPR-Cas9 knockout (CRISPR-KO) of the CNTFR/gp130/WSX-1 receptor reduces cell survival in AMD KO cybrids in vitro and blunts the protective effects of exogenous HNG, demonstrating the crucial role of this receptor in HNG-mediated cytoprotection.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×